At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 106 enrolled
Drug / intervention
Bimatoprost 0.03% +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues
In Brief
A Phase 4 clinical trial evaluating Bimatoprost 0.03%, travoprost 0.004%, and 1 other intervention for Open Angle Glaucoma and Ocular Hypertension. Completed, enrolled 106 participants across 1 site.
Detailed Summary
This study will evaluate hyperemia and ocular surface tolerability in patients on prostaglandin analogues
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpen Angle Glaucoma, Ocular Hypertension
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2007
First PostedOct 2007
Primary CompletionJul 2008
Study CompletionSep 2008
TodayJul 2026
First PostedOct 4, 2007
Enrollment StartSep 1, 2007
Primary CompletionJul 1, 2008
Study CompletionSep 1, 2008
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 18.7 years ago
Interventions
Bimatoprost 0.03%drug
bimatoprost 0.03%, 1 drop nightly for 3 months
travoprost 0.004%drug
travoprost 0.004% eye drops, 1 drop nightly for 3 months
latanoprost 0.005% eye dropsdrug
latanoprost 0.005%, 1 drop nightly for 3 months